Biovail Corporation received FDA approval for its NDA for Aplenzin (formerly known as BVF-033), a once-daily formulation of bupropion hydrobromide developed by Biovail for the treatment of depression in adults. Biovail remains partnership discussions for the commercialization rights for Aplenzin in the US.
The FDA approved Shire’s Vyvanse (lisdexamfetamine dimesylate) for the treatment of ADHD in adults. Vyvanse was first introduced in July 2007 for the treatment of ADHD in children aged 6 to 12 years.
